Transseptal Solutions , Ltd.

Transseptal Solutions, Ltd. specializes in cardiac transseptal access sets, such as the TSP Crosser Transseptal Access System. These devices are specifically designed for procedures that require crossing the septum (the wall dividing the heart chambers) during cardiac catheterization, enabling access for interventions like ablation or valve repairs.

Transseptal Solutions, Ltd. is based in the United States, which means its devices fall under FDA jurisdiction. The company’s products are classified as Class II devices, indicating a moderate level of regulatory scrutiny, as they are not considered low-risk (Class I) but also not high-risk (Class III). This classification requires compliance with FDA’s 510(k) premarket notification process and UDI (Unique Device Identification) requirements.

Transseptal Solutions, Ltd.’s devices are included in the FDA’s 510(k) registry, which tracks premarket submissions for Class II devices, and the FDA’s UDI (Unique Device Identification) system. These registries ensure transparency in device identification and compliance with regulatory requirements, helping healthcare providers and authorities verify product details and approval status.

Transseptal Solutions, Ltd.’s devices are classified as Class II under FDA regulations. This classification is based on the level of risk associated with the product—Class II devices require special controls beyond general controls (like good manufacturing practices) to ensure safety and effectiveness. For example, transseptal access sets are considered to have a moderate risk due to their use in invasive cardiac procedures, necessitating additional scrutiny and documentation.